Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (220)	2/27/1999 10:30:00 PM
From: tnsaf	Respond to of 1475

From Medimmune's web site: During 1998, the Company concluded a second clinical trial of MEDI-507, a Phase 1/2 study evaluating MEDI-507 for the treatment of GvHD in adult steroid-resistant stem cell transplant (SCT) or bone marrow transplant (BMT) patients. In one of the arms of this clinical trial, the MEDI-507 dosing regimen was extended past the initial 10 days of treatment. The data from this trial are currently being analyzed and the results are expected to be presented at a medical conference in 1999. In December 1998, the Company announced plans to initiate two additional Phase 1/2 clinical trials to evaluate MEDI-507. Both studies are expected to be completed in 1999. In the first study, adult steroid-naïve SCT or BMT recipients will receive MEDI-507 or placebo combined with corticosteroids (methylprednisolone) for initial treatment of acute GvHD. Because this study would be the first to evaluate MEDI-507 as part of initial treatment of GvHD, all patients are expected to receive the standard initial GvHD treatment with corticosteroids. It is anticipated that this Phase 1/2 trial will include up to 32 patients recruited from up to 15 centers. At year-end 1998, the trial protocol had been approved by the FDA, and patient recruitment had begun. In the second study, MEDI-507 will be assessed in an open-label trial for its ability to treat GvHD in pediatric SCT or BMT patients. Currently there are no agents approved for the treatment of GvHD in children. Up to 20 pediatric patients (age 2-17) are expected to be recruited from at least ten centers for this Phase 1/2 study. At year-end 1998, the clinical trial protocol had been submitted for approval to the FDA and if approved, the study would commence enrollment following the entry of initial patients in the adult trial. A Phase 1 clinical study evaluating MEDI-507 for the treatment of psoriasis is currently ongoing. The Company expects to have results from this trial in 1999.

To: scaram(o)uche who wrote (220)	3/1/1999 2:01:00 PM
From: JFitnich	Read Replies (1) \| Respond to of 1475

One more time: I am reading and copying directly from the RS NOTE here. (1) Results of Phase 1 trial of MEDI507 in psoriasis patients expected by mid-99 (2)Initiation of Phase 2 trial of MEDI-507 in patients with GvHD expected in 4Q:99 That all it says. My guess is that the PH 2 will be evaluating what the drug can do in patients receiving it longer than 10 days, something they started to do with the PH 1/2 announced in December. Like I said, it's just a guess. I'm not sure if RStephens is wrong or they know something none of the rest of us know. JF